

Oral Mucositis Market to Expand Significantly by 2034, States DelveInsight Report

DelveInsight's Oral Mucositis Market report offers an in-depth understanding of the epidemiology and market trends in the 7MM.

LAS VEGAS, NV, UNITED STATES,
January 28, 2025 /EINPresswire.com/ --

The Oral Mucositis market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Oral Mucositis pipeline products will significantly revolutionize the Oral Mucositis market dynamics.



DelveInsight's "Oral Mucositis Market Insights, Epidemiology, and Market Forecast-2034" report offers an in-depth understanding of the Oral Mucositis, historical and forecasted epidemiology as well as the Oral Mucositis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Oral Mucositis market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; [Oral Mucositis Market Forecast](#)

Some of the key facts of the Oral Mucositis Market Report:

- The Oral Mucositis market size is anticipated to grow with a significant CAGR during the study period (2020-2034)
- In May 2024, Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing treatments for rare diseases that currently lack effective options. Our Specialized BioTherapeutics division is advancing HyBryte™ (SGX301 or synthetic hypericin sodium), a novel photodynamic therapy that uses safe visible light to treat cutaneous T-cell lymphoma (CTCL). Following the successful completion of the second Phase 3 study, we plan to seek regulatory approvals for potential global commercialization. Additionally, this division is working on expanding the use of synthetic hypericin (SGX302) for psoriasis, our first-in-class innate defense regulator (IDR) technology, dusquetide (SGX942) for treating inflammatory

diseases such as oral mucositis in head and neck cancer, and SGX945 for Behçet's Disease.

- Increasing Incidence of cancer and emerging therapies, will fuel the Oral Mucositis market
- Oral mucositis refers to erythematous and ulcerative lesions of the oral mucosa observed in patients with cancer being treated with chemotherapy, and/or with radiation therapy to fields involving the oral cavity
- According to Claudio et al., about 40% of the patients treated with chemotherapy develop mucositis; this percentage rises to about 90% for head and neck cancer patients (HNC) treated with both chemo- and radiotherapy
- According to the analysis, the prevalence of oral mucositis ranges from 30% to 40% among the general cancer patient population.
- Key Oral Mucositis Companies: Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix, Monopar Therapeutics, MitolImmune Therapeutics, and others
- Key Oral Mucositis Therapies: KEPIVANCE (palifermin), Avasopasem manganese (GC4419), RRx-001, Avasopasem Manganese (GC4419), SGX942, Validive (Clonidine HCl), MIT-001, and others
- The Oral Mucositis epidemiology based on gender analyzed that a significantly greater risk of OM has been found in women than in men (86% vs. 60%), and their Oral Mucositis generally is more severe and lasts longer

Oral Mucositis Overview

Oral Mucositis is a painful inflammatory condition affecting the mucous membranes inside the mouth. It commonly occurs in patients undergoing cancer treatments, such as chemotherapy and radiation therapy, which can damage the rapidly dividing cells of the oral lining. Symptoms include soreness, ulcers, and difficulty eating or swallowing, significantly impacting a patient's quality of life. Management typically involves pain relief, maintaining oral hygiene, and, in some cases, medications to promote healing and prevent infections. Early recognition and intervention are crucial to mitigate the severity of this condition and improve patient outcomes.

Get a Free sample for the Oral Mucositis Market Report:

https://www.delveinsight.com/report-store/oral-mucositis-om-market?utm_source=einpresswire&utm_medium=pressrelease&utm_campaign=gpr

Oral Mucositis Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Oral Mucositis Epidemiology Segmentation:

The Oral Mucositis market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

- Total Prevalence of Oral Mucositis

- Prevalent Cases of Oral Mucositis by severity
- Gender-specific Prevalence of Oral Mucositis
- Diagnosed Cases of Episodic and Chronic Oral Mucositis

Download the report to understand which factors are driving Oral Mucositis epidemiology trends @ [Oral Mucositis Epidemiological Insights](#)

Oral Mucositis Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Oral Mucositis market or expected to get launched during the study period. The analysis covers Oral Mucositis market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Oral Mucositis Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Oral Mucositis Therapies and Key Companies

- KEPIVANCE (palifermin): Swedish Orphan Biovitrum
- Avasopasem manganese (GC4419): Galera Therapeutics
- RRx-001: EpicentRx
- Avasopasem Manganese (GC4419): Galera Therapeutics, Inc.
- SGX942: Soligenix
- Validive (Clonidine HCl): Monopar Therapeutics
- MIT-001: MitolImmune Therapeutics

Scope of the Oral Mucositis Market Report

- Study Period: 2020–2034
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Oral Mucositis Companies: Swedish Orphan Biovitrum, Galera Therapeutics, EpicentRx, Galera Therapeutics, Inc., Soligenix, Monopar Therapeutics, MitolImmune Therapeutics, and others
- Key Oral Mucositis Therapies: KEPIVANCE (palifermin), Avasopasem manganese (GC4419), RRx-001, Avasopasem Manganese (GC4419), SGX942, Validive (Clonidine HCl), MIT-001, and others
- Oral Mucositis Therapeutic Assessment: Oral Mucositis current marketed and Oral Mucositis emerging therapies
- Oral Mucositis Market Dynamics: Oral Mucositis market drivers and Oral Mucositis market barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG

Matrix, Market entry strategies

- Oral Mucositis Unmet Needs, KOL's views, Analyst's views, Oral Mucositis Market Access and Reimbursement

To know more about Oral Mucositis companies working in the treatment market, visit @ [Oral Mucositis Clinical Trials and Therapeutic Assessment](#)

Table of Contents

1. Oral Mucositis Market Report Introduction
2. Executive Summary for Oral Mucositis
3. SWOT analysis of Oral Mucositis
4. Oral Mucositis Patient Share (%) Overview at a Glance
5. Oral Mucositis Market Overview at a Glance
6. Oral Mucositis Disease Background and Overview
7. Oral Mucositis Epidemiology and Patient Population
8. Country-Specific Patient Population of Oral Mucositis
9. Oral Mucositis Current Treatment and Medical Practices
10. Oral Mucositis Unmet Needs
11. Oral Mucositis Emerging Therapies
12. Oral Mucositis Market Outlook
13. Country-Wise Oral Mucositis Market Analysis (2020–2034)
14. Oral Mucositis Market Access and Reimbursement of Therapies
15. Oral Mucositis Market Drivers
16. Oral Mucositis Market Barriers
17. Oral Mucositis Appendix
18. Oral Mucositis Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

To know more about our Competitive Services, Click here: [Pharma Competitive Intelligence About DelveInsight](#)

DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Gaurav Bora

DelveInsight Business Research

+1 469-945-7679

[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/781085217>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.